🇺🇸 FDA
Patent

US 11767367

Monoclonal antibody neo-201 for the treatment of human carcinomas

granted A61KA61K2039/505A61K38/05

Quick answer

US patent 11767367 (Monoclonal antibody neo-201 for the treatment of human carcinomas) held by PRECISION BIOLOGICS, INC. expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
PRECISION BIOLOGICS, INC.
Grant date
Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K38/05, A61K38/1725, A61K38/20